- Home
- PTGX vs RCKT Comparison
PTGX vs RCKT Comparison
Compare PTGX & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTGX
- RCKT
- Stock Information
- Founded
- PTGX 2006
- RCKT 1999
- Country
- PTGX United States
- RCKT United States
- Employees
- PTGX N/A
- RCKT N/A
- Industry
- PTGX Biotechnology: Pharmaceutical Preparations
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- PTGX Health Care
- RCKT Health Care
- Exchange
- PTGX Nasdaq
- RCKT Nasdaq
- Market Cap
- PTGX 4.0B
- RCKT 328.6M
- IPO Year
- PTGX 2016
- RCKT N/A
- Fundamental
- Price
- PTGX $78.51
- RCKT $3.97
- Analyst Decision
- PTGX Strong Buy
- RCKT Buy
- Analyst Count
- PTGX 8
- RCKT 13
- Target Price
- PTGX $74.13
- RCKT $12.88
- AVG Volume (30 Days)
- PTGX 1.6M
- RCKT 3.1M
- Earning Date
- PTGX 10-31-2025
- RCKT 11-03-2025
- Dividend Yield
- PTGX N/A
- RCKT N/A
- EPS Growth
- PTGX N/A
- RCKT N/A
- EPS
- PTGX 0.80
- RCKT N/A
- Revenue
- PTGX $209,180,000.00
- RCKT N/A
- Revenue This Year
- PTGX N/A
- RCKT N/A
- Revenue Next Year
- PTGX $142.86
- RCKT $3,592.75
- P/E Ratio
- PTGX $93.54
- RCKT N/A
- Revenue Growth
- PTGX N/A
- RCKT N/A
- 52 Week Low
- PTGX $33.31
- RCKT $2.19
- 52 Week High
- PTGX $93.25
- RCKT $18.17
- Technical
- Relative Strength Index (RSI)
- PTGX 57.68
- RCKT 56.54
- Support Level
- PTGX $73.08
- RCKT $3.67
- Resistance Level
- PTGX $76.08
- RCKT $4.06
- Average True Range (ATR)
- PTGX 4.55
- RCKT 0.27
- MACD
- PTGX -0.53
- RCKT 0.00
- Stochastic Oscillator
- PTGX 33.73
- RCKT 43.27
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.